Vitro SAB de CV ADR (VITOF)

Vitro SAB de CV ADR is a depositary receipt listed on OTC Markets that represents shares of Vitro, S.A.B. de C.V. The underlying issuer, through its subsidiaries, produces, processes, distributes, and sells inorganic chemical products across global markets. Its product range includes sodium carbonate and bicarbonate, calcium chloride, and sodium chloride, which are used in applications spanning automotive, glass, detergent, water treatment, pharmaceutical, food, oil, road deicing, and livestock sectors. Vitro was founded in 1909 and is headquartered in San Pedro Garza García, Mexico.


Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Overall Financial Health Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
OTC-VITO.F
$0.12
-88.5% Downside
Expensive
Not available
Not available
Good
0.0%
October 27, 2026
0.9x
2.4x
0.4x
117.2 M
222.5 M
12.5%
8.8%
4.0
71.4%
Valuation • Fair Value

Vitro SAB de CV ADR (OTC-VITO.F) Fair Value by Valuation Model

Review the available estimates for Vitro SAB de CV ADR (OTC-VITO.F), including Ben Graham Formula Value, EPV Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$0.12

Estimated downside of 88.5% versus the current market price.

Fair Value Confidence

Med

Confidence level for the primary fair value estimate.

Ben Graham Formula Value

$1.49

Classic Ben Graham valuation formula reference.

EPV Fair Value

$0.13

Earnings power value estimate.

Comps Fair Value

$0.11

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use the 5 available valuation references for Vitro SAB de CV ADR (OTC-VITO.F) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Vitro SAB de CV ADR (OTC-VITO.F)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

288.8 M

Current operating scale indicator.

Revenue Forecast

282 M

Forward revenue estimate.

EBITDA

11.257 M

Current operating profitability reference.

EBITDA Forecast

506.1 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Vitro SAB de CV ADR (OTC-VITO.F) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Vitro SAB de CV ADR (OTC-VITO.F)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Good

Positive financial-health read.

Piotroski Score

5

Mid-range quality score.

Beneish M-Score

-2.66

No elevated caution signal from this screen.

Altman Z-Score

4.0

Relatively strong balance-sheet zone.

FCF / Net Income

71.4%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Vitro SAB de CV ADR (OTC-VITO.F). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Vitro SAB de CV ADR (OTC-VITO.F)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

October 27, 2026

Days to Earnings

35

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Vitro SAB de CV ADR (OTC-VITO.F), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Technical Outlook

Technical Signals by Time Frame

Review the technical signals currently available for this stock across supported time frames.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Vitro SAB de CV ADR (OTC-VITO.F) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Vitro SAB de CV ADR (OTC-VITO.F) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Vitro SAB de CV ADR (OTC-VITO.F) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

FAQ Fast Investor Answers

Vitro SAB de CV ADR (OTC-VITO.F) Stock FAQ

Data-supported answers about Vitro SAB de CV ADR (OTC-VITO.F), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$0.12
Estimated downside 88.5%
Valuation Rating
Overvalued
Estimated downside of 88.5%
Financial Health
Good
Current financial-health read

The current fair value estimate for Vitro SAB de CV ADR (OTC-VITO.F) is $0.12. This implies an estimated downside of 88.5% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 88.5% versus the current market price.

The current financial health read for Vitro SAB de CV ADR (OTC-VITO.F) is Good. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Vitro SAB de CV ADR (OTC-VITO.F) is October 27, 2026.

The latest available data indicates no current dividend yield for Vitro SAB de CV ADR (OTC-VITO.F).

The current P/E ratio listed for Vitro SAB de CV ADR (OTC-VITO.F) is 0.9x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Vitro SAB de CV ADR is 117.2 M.

The current enterprise value listed for Vitro SAB de CV ADR is 222.5 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Vitro SAB de CV ADR is OTC-VITO.F, and the stock is listed on OTC Markets.

Vitro SAB de CV ADR (OTC-VITO.F) is listed on OTC Markets.

The current debt-to-total-capital ratio listed for Vitro SAB de CV ADR is 12.5%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Vitro SAB de CV ADR is 8.8%. Free float helps investors understand how much of the share base is available for public trading.